Document is current
Any future updates will be listed below
-
Authors
Lleó, Alberto
Cavedo, Enrica
Parnetti, Lucilla
Vanderstichele, Hugo
Herukka, Sanna Kaisa
Andreasen, Niels
Ghidoni, Roberta
Lewczuk, Piotr
Jeromin, Andreas
Winblad, Bengt
Tsolaki, Magda
Mroczko, Barbara
Visser, Pieter Jelle
Santana, Isabel
Svenningsson, Per
Blennow, Kaj
Aarsland, Dag
Molinuevo, José Luis
Zetterberg, Henrik
Mollenhauer, Brit
- License Information
-
More Information
Article History
First Online: 16 December 2014
Competing interests
: L.P. has served on advisory boards for Innogenetics. H.V. is a co-founder of ADx Neurosciences and a founder of Biomarkable. P.L. is a consultant for IBL and Innogenetics. A.J. is the founder and CSO of Atlantic Biomarkers and an advisor to Quanterix. P.J.V. has served on advisory boards for Bristol–Myers Squibb and Roche. K.B. has served on advisory boards for Eli Lilly, Kyowa Hakko Kirin Pharma, Pfizer and Roche. D.A. has received honoraria and/or research support from AbbVie Denmark, GE Health, GlaxoSmithKline, H. Lundbeck and Novartis. B. Mollenhauer has received honoraria from GlaxoSmithKline and Orion, and holds or has pending patents regarding methods of differential diagnosis of dementias, ELISA-based quantification of α-synuclein proteins in cerebrospinal fluid and peripheral blood products using 384-well plates, and microRNA expression profiling of cerebrospinal fluid. She serves as a consultant for Bayer Schering Pharma, and receives research support from Boehringer Ingelheim, Desitin Pharmaceuticals, GE Healthcare and Teva. The other authors declare no competing interests.
